RESTORE (Raptiva (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-Label, Multi-Centre, Phase IV Study of Subcutaneously Administered Raptiva (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva.

Trial Profile

RESTORE (Raptiva (Efalizumab) Evaluation of Safety and Treatment Optimization Registry) Observational, Open-Label, Multi-Centre, Phase IV Study of Subcutaneously Administered Raptiva (Efalizumab) in the Treatment of Adult Patients With Moderate to Severe Chronic Plaque Psoriasis Who Are Candidates for Treatment With Raptiva.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 24 Oct 2014

At a glance

  • Drugs Efalizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Acronyms RESTORE
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 22 Dec 2009 Planned end date changed from 1 May 2009 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 12 May 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 Mar 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top